<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01314170</url>
  </required_header>
  <id_info>
    <org_study_id>E01-ADA-VSUS-01-10</org_study_id>
    <nct_id>NCT01314170</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of Susanna Implant in Patients With Refractory Glaucoma.</brief_title>
  <official_title>Evaluation of Efficacy and Safety of Susanna Implant in Patients With Refractory Glaucoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adapt Produtos Oftalmológicos Ltda.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adapt Produtos Oftalmológicos Ltda.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study clinical multicenter, phase III, open-label, prospective character to evaluate the&#xD;
      efficacy and safety Susanna Implant in patients with refractory glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical trial multicenter, phase III,open-label, prospective character to evaluate the&#xD;
      efficacy and safety of Susanna Implant in patients with refractory glaucoma of both genders,&#xD;
      of any race, aged above 18 years and diagnosed with glaucoma refractory.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study clinical multicenter, phase III, open-label, prospective character to evaluate the efficacy and safety Susanna implant in patients with refractory glaucoma.</measure>
    <time_frame>180 days</time_frame>
    <description>Evaluate the effectiveness of implant susanna in patients with refractory glaucoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study clinical multicenter, phase III, open-label, prospective character to evaluate the efficacy and safety Susanna implant in patients with refractory glaucoma. &quot;</measure>
    <time_frame>180 days</time_frame>
    <description>Evaluate the safety of implant susanna in patients with refractory glaucoma. i</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Susanna Implant</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with refractory glaucoma neovascular type or that failed in trabeculectomy will undergo surgery to place implants Susana.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Susanna Implant</intervention_name>
    <description>device</description>
    <arm_group_label>Susanna Implant</arm_group_label>
    <other_name>ADA-VSUS-01-10</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Neovascular glaucoma group:&#xD;
&#xD;
          1. Patient with neovascular glaucoma whose intraocular pressures which must be above 21&#xD;
             in at least three measurements, at different times in at least two different days&#xD;
             during one month, despite maximum tolerated medical therapy.&#xD;
&#xD;
          2. Visual acuity better than hand movements in the study eye.&#xD;
&#xD;
          3. Patients 18 years or more.&#xD;
&#xD;
          4. Patients with fixed residence in the health district where the surgery will be&#xD;
             performed.&#xD;
&#xD;
          5. Patients who fit the term of consent.&#xD;
&#xD;
        Group post-trabeculectomy failure:&#xD;
&#xD;
          1. Patients diagnosed with primary open angle glaucoma, pseudoesfoliação, pigmented or&#xD;
             primary angle closure who underwent surgery with trabeculectomy procedure after&#xD;
             failure of at least two months of surgery. The pressure must be above 21 in at least&#xD;
             three measurements, at different times in at least two different days during one&#xD;
             month, despite maximum tolerated medical therapy.&#xD;
&#xD;
          2. Patients diagnosed with primary open angle glaucoma, pseudoesfoliação, pigmented or&#xD;
             primary angle closure who underwent surgery with trabeculectomy procedure after&#xD;
             failure of at least two months for surgery and who can not afford the expenses of&#xD;
             medical treatment. The pressure must be above 21 in at least three measurements, at&#xD;
             different times in at least two different days during one month.&#xD;
&#xD;
          3. Visual acuity better than hand movements in the study eye.&#xD;
&#xD;
          4. Patients 18 years or more.&#xD;
&#xD;
          5. Patients with fixed residence in the health district where the surgery will be&#xD;
             performed.&#xD;
&#xD;
          6. Patients who fit the term of consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Group post-trabeculectomy failure:&#xD;
&#xD;
          1. Presence of staphyloma that does not allow the procedure.&#xD;
&#xD;
          2. Presence of history of scleritis&#xD;
&#xD;
          3. Presence of psychiatric disorder that has required hospitalization.&#xD;
&#xD;
          4. Presence of retinal detachment surgery with placement of a buckle or track.&#xD;
&#xD;
          5. Presence of corneal opacity that could prevent the adequate view of the anterior&#xD;
             chamber.&#xD;
&#xD;
          6. Presence of shallow anterior chamber that would prevent the placement of the implant.&#xD;
&#xD;
          7. Presence of vitreous in aphakia or anterior chamber.&#xD;
&#xD;
          8. Presence of psychiatric disorder that has required hospitalization.&#xD;
&#xD;
        Neovascular glaucoma group:&#xD;
&#xD;
          1. Presence of staphyloma that does not allow the procedure.&#xD;
&#xD;
          2. Presence of history of scleritis.&#xD;
&#xD;
          3. Presence of corneal opacity that could prevent the adequate view of the anterior&#xD;
             chamber.&#xD;
&#xD;
          4. Presence of shallow anterior chamber that would prevent the placement of the implant.&#xD;
&#xD;
          5. Presence of vitreous in aphakia or anterior chamber.&#xD;
&#xD;
          6. Presence of retinal detachment surgery with placement of a buckle or track.&#xD;
&#xD;
          7. Presence of neovascular glaucoma or other secondary glaucoma.&#xD;
&#xD;
          8. Presence of psychiatric disorder that has required hospitalization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Remo Susanna, Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital das Clínicas de São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renato Lisboa, Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNIFESP - Universidade Federal de São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cláudia Galvão, Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitário Prof. Edgar Santos - BA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flávia Villas, Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>- Instituto brasileiro de Oftalmologia e prevenção da cegueira- BA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fábio Kanadani, Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitário São José - Belo Horizonte</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Augusto Paranhos, Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Augusto Paranhos, Investigator</last_name>
    <phone>55 11 3747-3312</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fernanda Lima, Coordinator</last_name>
    <phone>55 11 2151-0723</phone>
    <email>fernandalima@einstein.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein</name>
      <address>
        <city>São Paulo</city>
        <zip>05651-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Augusto Paranhos, Investigator</last_name>
      <phone>55 11 3747-3312</phone>
    </contact>
    <contact_backup>
      <last_name>Fernanda Lima, Coordinator</last_name>
      <phone>55 11 2151-0723</phone>
      <email>fernandalima@einstein.br</email>
    </contact_backup>
    <investigator>
      <last_name>Augusto Paranhos, Investigator</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>August 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2011</study_first_posted>
  <last_update_submitted>May 9, 2011</last_update_submitted>
  <last_update_submitted_qc>May 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>PHC - Pharma Consulting</name_title>
    <organization>Dr. Dagoberto Brandão</organization>
  </responsible_party>
  <keyword>Implant, glaucoma, refractory glaucoma.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

